FindTrial
Sign In

Incidence of Her 2 testing on pathology of patients with gastric cancer

"An observational study to determine the incidence of Her2 positivity in 100 consecative gastric cancers"

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2013/03/003461
Enrollment
100
Registered
2013-03-07
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- gastric cancer

Interventions

None listed

Sponsors

Tata Memorial centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 100 consecutive patients with gastric cancer who have a pathology specimen at our site

Exclusion criteria

Exclusion criteria: If histopathology blocks were not available

Design outcomes

Primary

MeasureTime frame
Rate of Her2 positivity in 100 consecutive Gastric cancer patientsTimepoint: Total duration of 6 month—

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable—

Countries

India

Contacts

Public ContactBhawna Sirohi
bhawna.sirohi@btinternet.com91-9930033980

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026